Quantcast

Latest Avandia Stories

2011-11-10 08:00:00

Judge Appoints Mediator to Avandia Product Liability Cases and Establishes a Time Limit in which The Cases Must Be Resolved Or They Will Begin Trials, Explains Ennis & Ennis, P.A. (PRWEB) November 10, 2011 Bloomberg Businessweek is reporting U.S. District Judge Cynthia Rufe pushed GlaxoSmithKline (GSK) and the Plaintiffs yesterday to resolve most of the remaining Avandia diabetes medication patient lawsuits by appointing a mediator to preside over settlement negotiations for an...

2011-11-06 08:00:00

Ennis & Ennis, P.A. explains the potential âœBig Pharmaâ settlement. (PRWEB) November 06, 2011 British pharmaceutical company, GlaxoSmithKline (GSK), agreed to pay the US government $3 billion to settle criminal and civil investigations, reports Ennis & Ennis, P.A. If approved, the federal settlement will be the largest settlement for GSK, which is accused of illegally pushing its drugs. The claims against GSK include illegal marketing of...

2011-09-23 07:00:00

Ennis & Ennis, P.A. Explains that States with a Statute of Limitations of More Than One Year for Product Liability Cases May Still Have Time to File Claims Arising from the Use of Avandia (PRWEB) September 23, 2011 U.S. District Judge Cynthia M. Rufe, the presiding judge on the federal Avandia litigation cases, denied GlaxoSmithKlineâs Statute of Limitations Motion to Dismiss. GlaxoSmithKline (GSK), the manufacturer of Avandia, filed a Motion to Dismiss over 60 lawsuits,...

2011-09-09 14:38:40

Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla., report they have created prototype drugs having powerful anti-diabetic effects, yet apparently free — at least in mice — of dangerous side effects plaguing some current diabetes medications. The researchers say that their “proof-of-principle” findings could lead to safer medications for Type 2 diabetes, which affects more than 25 million children and adults...

2011-09-05 11:23:24

Research offers hope for better treatments for diabetes patients In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch. The finding paves the way for the development of anti-diabetic therapeutics with minimal adverse side effects plaguing currently available drugs such as Avandia (rosiglitazone), scheduled to be removed from...

2011-02-23 13:31:31

Analysis highlights cardiovascular risk of fluid retention New research shows that medications which have raised safety concerns over heart attack and stroke risks may not have gotten approval from the Food and Drug Administration (FDA) if the cardiovascular effects of fluid retention had been better understood. Fluid retention may explain the increased risk of heart attacks and strokes of medications such as Vioxx®, Bextra®, and...

2010-11-16 00:00:52

The Avandia lawyers at Onder, Shelton, O'Leary & Peterson, LLC have created a web site providing information about Avandia and how it has been linked to tens of thousands of heart attacks and strokes and the latest news on Avandia lawsuits Saint Louis, MO (Vocus) November 15, 2010 The law firm of Onder, Shelton, O'Leary & Peterson, LLC has launched a new website dedicated to providing information about Avandia heart attack and stroke lawsuits and are offering a free Avandia lawyer...

2010-09-29 11:28:00

MIAMI, Sept. 29 /PRNewswire/ -- Leading tort lawyers and experts from around the country will gather on November 3, 2010 in Miami to discuss the litigation ramifications and medical issues surrounding the DePuy hip implant recall and the diabetes drug Avandia, according to Tom Hagy of HB Litigation Conferences, producer of the program. Bruce W. Steckler and Robert Brown, both of the Baron & Budd law firm and Ben W. Gordon Jr. of Levin Papantonio Thomas Mitchell Echsner Rafferty &...

173a18ddb9388dbd18360bf112619c0f1
2010-09-23 14:20:00

European regulators say that widely-used diabetes drug Avandia should be pulled from the market, but U.S. officials have allowed it to stay. The U.S. Food and Drug Administration in Washington and the European Medicines Agency (EMA) said in separate statements that they agreed on the risks associated with the drug but had reached different conclusions on action. Avandia was once Glaxo's second-biggest selling drug, but sales have dropped in recent years. "The decisions are not surprising,...

2010-09-23 10:48:00

LONDON, Sept. 23 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE and LSE: GSK) confirms that following a review of Avandia® (rosiglitazone maleate) by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), each agency has today announced their individual regulatory decisions and the resulting actions. In the European Union*, the EMA has suspended the marketing authorization for all rosiglitazone-containing medicines (Avandia,...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related